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Abstract
TRK oncoproteins are chimeric versions of the NTRK1/NGF receptor and display constitutive tyrosine kinase activity leading
to transformation of NIH3T3 cells and neuronal differentiation of PC12 cells. Signal Transducer and Activator of Transcription
(STAT) 3 is activated in response to cytokines and growth factors and it has been recently identified as a novel signal
transducer for TrkA, mediating the functions of NGF in nervous system. In this paper we have investigated STAT3
involvement in signalling induced by TRK oncogenes. We showed that TRK oncogenes trigger STAT3 phosphorylation both
on Y705 and S727 residues and STAT3 transcriptional activity. MAPK pathway was involved in the induction of STAT3
phosphorylation. Interestingly, we have shown reduced STAT3 protein level in NIH3T3 transformed foci expressing TRK
oncogenes. Overall, we have unveiled a dual role for STAT3 in TRK oncogenes-induced NIH3T3 transformation: i) decreased
STAT3 protein levels, driven by TRK oncoproteins activity, are associated to morphological transformation; ii) residual STAT3
transcriptional activity is required for cell growth.
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Introduction
TRK oncogenes, isolated from papillary thyroid tumors [1],
represent rearranged versions of the NTRK1 gene, coding for
Nerve Growth Factor (NGF) receptor, also named TRKA.
Chromosomal rearrangements juxtapose the NTRK1 tyrosine
kinase domain to N-terminal portion of unrelated genes,
generating chimeric oncogenes named TRK, TRK-T1, TRK-
T2 and TRK-T3 [2]. TRK oncoproteins display constitutive
tyrosine kinase activity, promoted by coiled-coil domains provided
by the activating genes [2], thus mimicking the biochemical and
biological effects of NTRK1 receptor activated by NGF [3,4]. The
mechanism of action of TRK oncoproteins and their intracellular
signal transduction has been in part elucidated. This has been
performed by expressing the TRK oncogenes in different
mammalian cell systems; among these, NIH3T3 and PC12 cell
lines, which represent a useful model for studying in vitro oncogene-
triggered transformation and neuronal-like differentiation, respec-
tively [3,4]. Interactions of TRK oncoproteins with several signal
transducers (SHC, FRS2, FRS3, IRS1, IRS2, PLC-c and SHP-1),
leading to activation of the MAPK (Mitogen-Activated Protein
Kinase) pathway, have been identified, and their role in the
process of oncogenic transformation has been elucidated [5–8].
Nevertheless, more studies are required in order to fully dissect the
mechanism of action of TRK oncogenes.
Signal Transducer and Activator of Transcription (STAT) 3 is a
member of a gene transcription protein family initially discovered
as cytokine signal transducers, and subsequently found involved in
the signaling of growth factor tyrosine kinase receptors, cytoplas-
mic tyrosine kinases and oncogenes [9–11]. Conventional STAT3
activation consists in phosphorylation on a single tyrosine residue
(Y705) resulting in dimerization of the STAT1/3 transcription
factors, translocation into the nucleus and transcriptional activa-
tion of target genes [10,12]. In addition to phosphorylation on
Y705, phosphorylation on serine 727 (S727) residue enhances the
transcriptional activity of STAT3. Cooperation of phosphorylated
Y705 and S727 is necessary for full activation of STAT3 [13]; on
the other hand, S727 phosphorylation is sufficient to activate
STAT3 signaling independently of Y705 phosphorylation
[14–16]. Different cellular systems may affect STAT3 Y705 or
S727 phosphorylation as different protein kinases may be
implicated [17,18].
STAT3 is involved in a variety of biological processes including
cell proliferation and carcinogenesis [19]. Constitutive STAT3
activation has been found in multiple types of tumors, including
melanoma, prostate cancer, head and neck squamous cell
carcinoma [20,21], and inactivation of STAT3 has been found
to inhibit a variety of malignancies [19,22]. STAT3 is involved in
the signal transduction pathway of several oncogenic tyrosine
kinases, including v-src, NPM-ALK, RET-MEN2A and RET/
PTC oncogenes [11,23–25].
In addition to its nuclear function as transcription factor,
STAT3 exerts transcriptional independent function in regulating
cell migration [26]. In particular, cytoplasmic STAT3 plays a role
in mediating microtubules (MTs) dynamics through functional
interaction with stathmin, a key MT-destabilizing protein [27,28].
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TrkA, suggesting a role of STAT3 in the nervous system [29]. In
PC12 cells, activation of TrkA by NGF triggered STAT3
phosphorylation at S727, enhancing its DNA binding and
transcriptional activities; by contrast, no STAT3 Y705 phosphor-
ylation was induced by NGF treatment. STAT3 activation
induced by TrkA mediates several downstream functions of
NGF signaling, in particular cyclin D1 expression and neuronal
differentiation.
In this paper we investigated STAT3 involvement in the
signalling triggered by TRK oncogenes in different cellular
systems, such as PC12 and NIH3T3 cells. In particular we
showed that TRK oncogenes induced Stat3 phosphorylation,
both on Y705 and S727, and Stat3 transcriptional activity,
partially through MAPK pathway. We have unveiled a dual
role for STAT3 in TRK oncogenes-induced NIH3T3 transfor-
mation: i) decreased Stat3 protein levels, driven by TRK
oncoproteins activity, are associated to morphological transfor-
mation; ii) residual Stat3 transcriptional activity is required for cell
growth.
Results
TRK Oncogenes Induce STAT3 Phoshorylation and
Transcriptional Activity
A recent report has shown that Stat3 is involved in the
intracellular signalling triggered by the TrkA receptor. In PC12
cells the stimulation of TrkA by NGF induces Stat3 phosphory-
lation on S727 but not on Y705, enhances its DNA binding and
transcriptional activities; therefore Stat3 mediates several down-
stream effects of NGF, including neuronal differentiation [29].
We have previously shown that TRK oncogenes, chimeric
versions of the TRKA receptor containing its tyrosine kinase
domain [30], induce neuronal like differentiation of PC12 cells
thus mimicking the effect of NGF treatment [3]. To investigate
whether STAT3 is involved in signalling of TRK oncogenes, we
analyzed Stat3 phosphorylation status by Western blot analysis
with anti-phosphoSTAT3 S727 and Y705 antibodies in PC12 cells
transiently transfected with TRK oncogenes (Figure 1A). In mock
transfected PC12 cells NGF stimulation of endogenous TrkA
receptor induced Stat3 phosphorylation on S727 but not on Y705
residues, in accordance to literature data [29]. By contrast, the
expression of TRK and TRK-T3 oncogenes induced Stat3
phosphorylation on both S727 and Y705 residues. This discrep-
ancy is related to protein expression level; in fact phosphorylation
of both Stat3 residues was observed in NGF-treated PC12 cells
overexpressing the TRKA receptor. Expression levels of trans-
fected TRKA receptor and TRK oncoproteins are shown in the
second panel; in these conditions endogenous TrkA expression was
not detectable, however its tyrosine phosphorylation was observed
in TRK immunocomplexes following NGF stimulation (Figure 1A
bottom panel).
STAT3 phosphorylation promotes its dimerization and nuclear
translocation, followed by transcription of target genes [10,12]. To
analyze whether TRK oncogenes-induced STAT3 phosphoryla-
tion correlated with STAT3 dependent transcriptional activity, we
performed STAT3 transactivation luciferase assay. HeLa cells
were transfected with pM67 plasmid, containing the luciferase
gene under the control of STAT3 responsive elements, in
combination with TRK constructs or empty vector, and assessed
for STAT3-dependent transactivation. In the luciferase assay
shown in Figure 1B (left panel), a marked effect of TRK-T3 and
TRK oncogenes was observed, as they induced a 30 and 22 fold
increase of STAT3 transcriptional activity relative to control,
whereas TRK-T1 effect was undetectable. Overexpression of
STAT3 by cDNA transfection (Figure 1B, right panel) unveiled
that also TRK-T1 is able to induce STAT3 transcriptional
activity, although with reduced efficiency with respect to TRK-T3
and TRK oncogenes.
In PC12 cells NGF-induced Stat3 S727 phosphorylation is
mediated by distinct signaling pathways, including MAPK [29]. As
MAPK pathway is involved in TRK oncoproteins signalling, we
evaluated the effect of its inhibition on TRK oncogenes-induced
Stat3 phosphorylation in PC12 cells (Figure 1C). In mock
transfected PC12 cells, treatment with the MEK inhibitor
UO126 reduced Stat3 S727 phosphorylation induced by NGF
stimulation of endogenous TrkA receptor, in accordance to
literature data [29]. In PC12 cells expressing TRK and TRK-
T3 oncogenes, UO126 treatment reduced Stat3 phosphorylation
on S727; by contrast, no effect was observed on Stat3 Y705
phosphorylation. TrkA, TRK-T3 and TRK kinase activity was
not affected by the MEK inhibitor, as demonstrated by their
capability to phosphorylate Shc adaptor. Phosphorylated and total
ERK1/2, and TRK oncoproteins levels are shown in lower panels
as control. On the whole data reported in Figure 1C suggest that
in PC12 cells ERKs activation, induced by stimulated TrkA
receptor and TRK oncogenes, is responsible for STAT3 S727 but
not Y705 phosphorylation.
Analysis of Stat3 in NIH3T3 Cells Expressing TRK
Oncoproteins
To investigate the role of STAT3 in TRK oncogenes-induced in
vitro transformation, we analysed Stat3 phosphorylation in
NIH3T3 cells expressing TRK oncoproteins. As shown in
Figure 2A, transient expression of TRK-T1, TRK-T3 and TRK
oncogenes increased Stat3 phosphorylation on Y705 but not on
S727. The luciferase reporter assay in Figure 2B showed that
STAT3-dependent transcriptional activity was increased in cells
expressing TRK oncogenes, indicating their capability to activate
STAT3.
We next analyzed Stat3 status in NF861 and NF797 cells,
NIH3T3-derived transformed foci stably expressing TRK-T1 and
TRK-T3 oncogenes respectively [4,31] (Figure 2C). Surprisingly,
by Western blot analysis we observed that Stat3 protein level was
reduced in NF861 and NF797 compared to NIH3T3 by
approximately 50%, as indicated by densitometric analysis of
Stat3 protein normalized for vinculin levels. The signals detected
with anti phosphoSTAT3 antibodies correlate to Stat3 protein
amounts. Vinculin levels, shown as control, indicated similar
protein amount load.
To explore the mechanism involved in Stat3 down-regulation
in NIH3T3-derived foci, we investigated Stat3 mRNA expression
by RT-PCR in NIH3T3, NF861 and NF797 cells. Densitometric
analysis of Stat3 PCR products, normalized for HPRT levels,
showed a reduction of STAT3 mRNA by approximately 50% in
NF861 and NF797 compared to NIH3T3 cells (Figure 2D),
thus suggesting a down-regulation of Stat3 at the transcriptional
level.
Following activation by phosphorylation, STAT3 translocates to
the nucleus where it acts as a transcription factor; therefore
nuclear levels of STAT3 are important for its transcriptional
activity. To investigate nuclear Stat3 levels in parental NIH3T3
and NF861 and NF797 transformed cells, we performed cell
fractionation and assayed for STAT3 protein levels. As shown in
Figure 2E, reduced levels of Stat3 protein were confirmed in both
cytoplasm and nucleus of NF861 and NF797 with respect to
NIH3T3 cells. Comparison of cytoplasmic versus nuclear Stat3
levels did not highlight significant differences among cell lines in
STAT3 and TRK Oncogenes
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histone H1 levels are shown as controls for cytoplasmic and
nuclear fractions, respectively.
To assess whether different Stat3 protein amounts result in
different Stat3 transcriptional activity in NIH3T3 parental and
transformed cell lines, we performed STAT3-dependent luciferase
reporter assay. NIH3T3, NF861 and NF797 cells were transfected
with pM67 luciferase reporter vector and assessed for STAT3-
dependent transactivation. As shown in Figure 2F (top), despite the
reduced Stat3 protein levels (see Figure 2C) the Stat3 activity in
NF861 and NF797 foci is equivalent to that in NIH3T3 cells. In
addition, overexpression of STAT3 produced a drastic increase of
luciferase activity in NF861 and NF797 compared to NIH3T3
cells (Figure 2F, bottom).
Reduction of Stat3 Level Is Associated with
Morphological Transformation Induced by TRK
Oncogenes Activity
To investigate whether TRK kinase activity accounted for
reduced Stat3 levels in NIH3T3 foci expressing TRK oncogenes,
we treated NIH3T3, NF861 and NF797 cells with TRK kinase
inhibitor K252a, and analysed Stat3 protein levels by Western
blotting and densitometry (Figure 3A). Treatment of NF861 and
NF797 cells with K252a abrogated TRK oncoproteins tyrosine
Figure 1. STAT3 activation by TRK oncogenes. (A) Western blot analysis of PC12 cells transfected with empty pRC/CMV vector, TRKA, TRK-T3,
and TRK cDNAs. NGF treatment (50ng/ml, 109) is indicated. Cell lysates and immunocomplexes were separated by SDS PAGE as described in Material
and Methods and immunoblotted with indicated antibodies. In the bottom panel two distinct exposures of the same blot were used for
documenting TRKA or TRK oncoproteins phosphorylation. (B) HeLa cells were co-transfected with pM67 and pRL-TK in combination with the
indicated TRK oncogene cDNAs in the absence (left graph) or presence (right graph) of STAT3 cDNA and assayed for STAT3-dependent luciferase
activity 48 hours later. Activity is expressed as the ratio of luciferase/renilla activity, and reported as fold-inductions over empty vector (left panel) or
STAT3 (right panel) (RLA: Relative Luciferase Activity). The data represent the mean values 6 SD of triplicate samples. Similar results were obtained in
three independent experiments. (C) MAPK involvement in TRK-induced Stat3 phosphorylation. Western blot analysis of PC12 cells transfected with
empty pRC/CMV vector, TRK-T3 or TRK cDNAs. NGF (109, 50ng/ml) and UO126 (16 hr, 10 mM) treatments are indicated. Immunoblotting was
performed with the indicated antibodies.
doi:10.1371/journal.pone.0009446.g001
STAT3 and TRK Oncogenes
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Stat3 protein level was detected in NIH3T3 cells. On the contrary,
K252a increased Stat3 levels in NF861 and NF797 foci. Cells
exposed overnight to K252a showed a marked increase of Stat3
level (50% and 70%, respectively) and phenotypic reversion of
transformed morphology (Figure 3D), suggesting a correlation
between TRK oncoproteins activity, transformed phenotype and
low Stat3 levels.
Involvement of MAPK pathway in the regulation of Stat3
protein levels was also investigated (Figure 3B). Inhibition of
MAPK pathway by UO126, which cause a partial reversion of the
transformed phenotype (Figure 3D), induced an increase of Stat3
protein levels in NF861 and NF797 cells, indicating that MAPK
activity triggered by TRK oncogenes is involved in the regulation
of Stat3 protein levels. No effect of UO126 treatment was
observed on phosphorylated TRK; phosphorylated ERK1/2, total
ERK1/2 and vinculin levels are shown in lower panels as controls.
Recently, a role for cytoplasmic STAT3 has been described
[26]. In particular, STAT3 has been related to microtubules (MTs)
stabilization, by preventing the disassembly of MTs induced by the
interacting partner stathmin. To explore a possible correlation
between low levels of Stat3 in NF861 and NF797 cells and MTs
destabilization, we analyzed the amount of acetylated a-tubulin, a
marker of MTs stabilization, in cells untreated or treated with
K252a. As shown in Figure 3C, acetylated a-tubulin levels were
less abundant in NF861 and NF797 cells compared to NIH3T3
cells, indicating MTs disorganization in transformed cells. Such
disorganization was visible in a-tubulin immunostaining of NF797
Figure 2. Analysis of Stat3 in NIH3T3 cells expressing TRK oncoproteins. (A) Western blot analysis of NIH3T3 cells transiently transfected
with TRK oncogenes. Cells were transfected as described in Materials and Methods, cell lysates and immunocomplexes separated by SDS PAGE and
immunoblotted with the indicated antibodies. (B) NIH3T3 cells were co-transfected with pM67 and pRL-TK in combination with the indicated TRK
oncogene and STAT3 constructs and assayed for STAT3-dependent luciferase activity 48 hours later. Activity is expressed as the ratio of luciferase/
renilla activity, and reported as fold-inductions over STAT3 basal activity (RLA: Relative Luciferase Activity). The data represent the mean values 6 SD
of triplicate samples. Similar results were obtained in two independent experiments. (C) Cell extracts from NIH3T3, NF861 and NF797 cells were
immunoblotted with the indicated antibodies. Images were acquired by Biorad ChemiDoc and densitometric analysis of the bands was performed by
Image Quant software. Data are expressed as ratio STAT3/vinculin and normalized for NIH3T3 sample. (D) RT PCR analysis of Stat3 expression. Stat3
and HPRT fragments were obtained as described in Material and methods and separated on 2% agarose gel. Images were acquired by Biorad GelDoc
and densitometric analysis of the bands was performed by Image Quant software. Densitometric values are expressed as ratio Stat3/HPRT and
normalized for NIH3T3 sample. Data represent the mean values 6 SD of four independent experiments. (E) Cytoplasmic and nuclear extracts from
NIH3T3, NF861 and NF797 cells were obtained as described in Material and methods and subjected to Western blot analysis with the indicated
antibodies. (F) NIH3T3, NF861 and NF797 cells were co-transfected with pM67 and pRL-TK in combination with the indicated TRK oncogene, alone
(upper panel) or in combination with STAT3 construct (bottom panel) and assayed for STAT3-dependent luciferase activity 48 hours later. Activity is
expressed as the ratio of luciferase/renilla activity, and reported as fold-inductions over STAT3 activity in NIH3T3 cells. Experiments were performed in
triplicates; data represent the mean values of three independent experiments. RLA: Relative Luciferase Activity.
doi:10.1371/journal.pone.0009446.g002
STAT3 and TRK Oncogenes
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(Figure 3D). Following overnight treatment with K252a, the
fraction of acetylated a-tubulin raised in NF861 and NF797, along
with Stat3 protein increase (Figure 3C). Concomitantly, NF861
and NF797 cells display MTs organization and cell morphology
similar to naı ¨ve NIH3T3 cells (Figure 3D). This suggests that cell
shape, MTs stabilization and Stat3 levels may be linked in
NIH3T3-derived foci expressing TRK oncogenes.
Role of Stat3 in TRK-Induced Cell Growth
STAT3 protein is activated in response to growth factor and
cytokines and promotes cell proliferation and survival [10]. We
investigated the effect of inhibition of Stat3 activity in NF861 and
NF797 by using S3I-201 (also named NSC 74859), a chemical
inhibitor which interferes with STAT3 complex formation and
affects its DNA-binding and transcriptional activity [32]. NF861
and NF797 foci, and NIH3T3 cells as control, treated with SI3-
201 inhibitor for 48 hours did not show any morphological change
(Figure 4A), suggesting that Stat3 transcriptional activity is not
involved in foci transformed phenotype. We next determined the
effect of S3I-201 an NF861 and NF797 cell growth by
fluorometric cell viability assay. As shown in Figure 4B, S3I-201
reduced the growth rate of NF861 and NF797 (40 and 50%
reduction at 24 hours; 50 and 85% reduction at 48 hours,
respectively), indicating an important role of Stat3 in TRK
oncogenes induced cell proliferation. Reduction in cell number
after 48 hours treatment with SI3-203 was confirmed by cell count
(data not shown). In the same conditions, no evidence of apoptosis
or necrosis was observed in NF861 and NF797 cells by FACS
analysis (data not shown).
Since cyclin D1 is one of STAT3 major targets and is involved
in cell proliferation, we analyzed whether treatment with STAT3
inhibitor may affect cyclin D1 expression in NF861 and NF797
foci compared to NIH3T3 cells. As shown in Figure 4C, cyclin D1
expression was higher in transformed foci than in parental
NIH3T3 cells. Treatment with S3I-201 did not cause reduction
Figure 3. Reduction of Stat3 level is associated to morphological transformation induced by TRK oncogenes activity. (A) NIH3T3,
NF861 and NF797 cells were treated with K252a (200nM) for the indicated time; cell lysates were processed and immunoblotted with the indicated
antibodies. Densitometric analysis of the bands is reported in the bottom panel. Images were acquired by Biorad ChemiDoc and analysed with Image
Quant software. Data are reported as ratio of STAT3/vinculin and normalized over untreated samples for any cell line. (B) Cell extracts from NIH3T3,
NF861 and NF797 cells treated with K252a (200nM, 16 hr) were analyzed by Western blot with the indicated antibodies. (C) Cell extracts from NIH3T3,
NF861 and NF797 cells treated with UO126 (10 mM, 16 hr) were analyzed by Western blot with the indicated antibodies. (D) Phase contrast images
(top) and a-tubulin immunostaining (bottom) of NIH3T3 cells, NF797 cells treated or not with K252a (200nM, overnight) or UO126 (10 mM).
doi:10.1371/journal.pone.0009446.g003
STAT3 and TRK Oncogenes
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induction by TRK oncogenes may be mainly driven by pathways
different from STAT3.
Discussion
STAT3 is a pleiotropic factor activated by many different
signals including cytokines, growth factors and oncogenes, and it
mediates cellular proliferation, differentiation, survival and
immune function [12]. Recently it has been shown that Stat3 is
activated in response to NGF through phosphorylation of S727
residue and mediates its neurotrophic effects [29]. In this work, we
have investigated Stat3 involvement in TRK oncogenes signalling
in different cellular systems such as PC12 and NIH3T3 cells.
We have observed that in PC12 cells TRK oncogenes expression
induced Stat3 phosphorylation on both Y705 and S727 residues,
whereas NGF stimulation of endogenous TrkA receptor increased
only S727 phosphorylation, in agreement with literature data [29].
This discrepancy is probably due to different expression levels, since
overexpression of TRKA receptor in PC12 cells drives also Stat3
phosphorylation on Y705 in response to NGF. In a previous work
Ng et al, who firstly showed the absence of Y705 Stat3
phosphorylation in NGF stimulated PC12 cells, have hypothesized
either the presence of a potential intrinsic dephosphorylation
mechanism of Y705, or inhibition of Y705 phosphorylation
triggered by phosphorylated S727 [29]. Our findings that Stat3
Y705 phosphorylation is triggered by TRKA receptor and TRK
oncoproteins, suggests a dephosphorylation mechanism as the most
likely. In this view, overexpression of TRK proteins might perturb
the equilibrium of a putative dephosphorylation mechanism which
may lead to detection of Y705 phosphorylation. No evidence of
direct association between Stat3 and TrkA receptor has been
previously shown; similarly, in our experimental conditions, we
failed to detect interaction between Stat3 and TRK oncoproteins.
Nevertheless, we can not exclude a possible direct phosphorylation
of Stat3 on Y705 by TRKA receptor and TRK oncoproteins. More
studies will be required to unveil the precise mechanism and the
kinase(s) involved in Y705 STAT3 phosphorylation and the
pathways implicated. We have determined that in PC12 cells Stat3
activation by TRK oncoproteins requires signalling through
MAPK, as UO126 treatment affected Stat3 phosphorylation on
S727 but not on Y705. This is in keeping with the hypothesis that
Y705 could be phosphorylated eitherdirectly by TRKoncoproteins
or by alternative pathways.
It has been proposed that phosphorylation of S727 may be
mediated by different mechanisms in different experimental
Figure 4. Role of Stat3 in TRK-induced cell growth of NIH3T3 derived foci. (A) Phase contrast images of NF861, NF797 and NIH3T3 cells
treated or not with S3I-201 (100 mM, 48 hr). (B) Cell viability of NF861 and NF797 cells treated with DMSO (0.3%) or S3I-201 (100 mM) determined by
the Alamar Blue cell viability assay. (C) Western blot analysis of NIH3T3, NF861 and NF797 cells treated with S3I-201 (100 mM, 48 hr). Samples were
immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0009446.g004
STAT3 and TRK Oncogenes
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that Stat3 S727 is phosphorylated in PC12 but not in NIH3T3
cells transiently transfected with TRK oncogenes.
In a model of in vitro transformation represented by NIH3T3
cells transformed by TRK oncogenes (NF861 and NF797) we
observed reduction of Stat3 protein levels, but no difference in
Stat3 cellular localization in comparison to parental NIH3T3 cells.
Reduction of Stat3 in NIH3T3 foci is related to increased
microtubules destabilization, as indicated by reduced acetylated a-
tubulin and transformed cell morphology. When TRK oncopro-
teins activity was blocked by K252a inhibitor, NIH3T3 foci
underwent morphological reversion and STAT3 protein raised to
a level comparable to NIH3T3 cells, indicating that Stat3
reduction in transformed foci correlated to morphological features
of transformation driven by TRK kinase activity. We have
previously shown that ERK activation is crucial for TRK
oncogenic activity: abrogation of signalling through SHC adapter,
affecting MAPK activation, impairs TRK-T3 transforming
activity [5] and inhibition of MEK by UO126 treatment lead to
morphological reversion of NF861 and NF797. Similarly to
inhibition of TRK kinase activity, inhibition of MAPK pathway
lead to reduction of STAT3 protein level. Interestingly, reduction
of STAT3 levels may be common feature of NIH3T3 transformed
foci, as it has already been observed in NIH3T3 cells transformed
by Ha-rasV12 oncogene [33], and by other oncogenes such as
TPR-MET, RET/PTC1 and COLA1/PDGF (our unpublished
results).
Our data support the notion that decrease of STAT3 is part of
the in vitro transformation program as it is associated to the
destabilization of MTs typical of transformed NIH3T3 cells. This
is in agreement with a recently described transcriptional
independent role of STAT3 in mediating MTs dynamics and cell
migration through a direct functional interaction with stathmin
[27]. An intriguing hypothesis would be that reduced Stat3 levels
in the cytoplasm may render stathmin, no longer sequestered by
Stat3, more available to interact with tubulin and therefore
destabilize MTs. More recently it has been shown that Stat3
modulates Rac1 independently from Stat3 transcriptional activity.
Loss of Stat3 expression in mouse embryonic fibroblasts (MEF)
drives increased Rac1 activity, and this promotes a random mode
of migration by reducing directional persistence and formation of
actin stress fibers [34]. It is interesting to note that WT MEF
exhibit a classical polarized phenotype, whereas MEFs not
expressing Stat3 display a non-polarized phenotype very similar
to the one of NIH3T3-derived transformed foci.
In Ha-rasV12 transformed NIH3T3 cells, Stat3 reduction is
due to regulation of proteasomal degradation of the protein
[33]. This mechanism is not involved in TRK oncogenes-
induced Stat3 reduction, as treatment of NF861 and NF797
cells with the proteasome inhibitor lactacystin did not induce
any Stat3 protein change (data not shown). Instead, we have
observed a reduction of Stat3 mRNA in foci expressing TRK
oncogenes compared to NIH3T3 cells, indicating a transcrip-
tional regulation of Stat3 by TRK-T1 and TRK-T3 oncogenes
in transformed foci. Several observations [35–37] lead to the
hypothesis that cyclin D1 overexpression may down-regulate
STAT3 expression. This may occur in NIH3T3 foci expressing
TRK oncogenes in which cyclin D1 is overexpressed compared
to parental NIH3T3 cells.
Despite the reduced protein level, in NF797 and NF861 cells
Stat3 transcriptional activity is comparable to parental NIH3T3
cells and it is required for cell growth, as demonstrated by
treatment with S3I-201, a compound inhibiting STAT3 tran-
scriptional activity by interfering with dimer formation.
On the whole, the data presented in this work unveil a dual role
of Stat3 in in vitro transformation triggered by TRK oncogenes: 1)
reduced Stat3 levels are linked to morphological transformation
typical of NIH3T3 foci; 2) the transcriptional activity of the
residual Stat3 amount is necessary for cell growth.
Materials and Methods
Plasmids
T3/WT, pC24B (TRK-T1 construct), pDM16 (TRK construct)
have been previously described [3–5,38]. pRC-STAT3 flag
plasmid [11] was kindly provided by Dr. Darnell (Rockfeller
University, NY). For luciferase assay pTATA(TK)Luc4xM67
(kindly provided by Dr. Darnell, and referred in the text as
pM67) and pRL-TK (Promega, Madison, WI) were used.
Cell Culture and Transfection
NIH3T3, NF861 and NF797 cell lines were grown in DMEM
supplemented with 10% and 5% Calf Serum (Colorado Company,
CO), respectively, and maintained in 10% CO2 humidified
atmosphere. HeLa cells were grown in DMEM supplemented
with 10% FCS; PC12 cells were grown in RPMI supplemented
with 5% FCS and 10% Horse serum and maintained in 5% CO2
humidified atmosphere. Parental and derived NIH3T3 cell lines
were transfected with Lipofectamine2000 (Invitrogen, Carlsbad,
CA) according to manufacturer’s instruction. PC12 cells were
transfected with CellFECTINE reagent (Invitrogen, Carlsbad,
CA). HeLa cells were transfected with FuGENE6 reagent (Roche,
Manheim, Germany) according to manufacturer’s instruction.
NGF was from Upstate Biotechnology; UO126 was purchased
from Promega (Madison, WI); K252a and S3I-201 (also named
NSC 74859) were from Calbiochem (San Diego, CA). Treatments
were performed as described in Figure legends.
Western Blot Analysis
Cell lysates were produced in RIPA modified buffer (20mM
Tris-HCl, pH 7.4, 150mM NaCl, 5mM EDTA, 1% NonidetP-40)
supplemented with Complete Mini EDTA-free protease Inhibitor
Cocktail (Roche), 1mM NaVO4 and 1mM PMSF. Protein
samples (20–50 mg) were boiled in NuPAGE LDS sample buffer
(Invitrogen, Carlsbad, CA) and separated on 7%, 10% or 4–12%
SDS-PAGE (NuPAGE Novex- Invitrogen, Carlsbad, CA) with the
appropriate running buffer (Tris-Acetate, MOPS, MES), then
transferred onto nitrocellulose filters and immunoblotted with the
appropriated antibodies.
Cell fractionation was performed using the ProteoExtract
Subcellular Proteome Extraction (S-PEK) Kit (Calbiochem, San
Diego, CA) according to manufacturer’s instructions.
The anti-STAT3, anti-phosphoSTAT3 S727, anti-phospho-
STAT3 Y705 were from Cell Signal Technology (Beverly, MA);
anti-TRK (C-14), cyclinD1 (DSC-6) and anti histone H1
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-vinculin, anti-phosphoERK1/2, anti ERK1/2,
anti acetylated a-tubulin, anti a-tubulin, anti a-tubulin were
purchased from SIGMA. The immuno-reactive bands were
visualized using horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (GE Healthcare).
Luciferase Assay
Cells (5610
4) were seeded in 24-well plates and transfected with
150 ng of pM67 plasmid, 50 ng of pRL-TK (Promega, Madison,
WI), and 250 ng of the plasmid of interest. The total amount of
transfected DNA was kept constant by adding empty pCDNA3-
myc vector. Forty-eight hours after transfection cell extracts were
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Luciferase Reporter
R Assay (Promega, Madison, WI) according to
manufacturer’s protocol. The experiments were performed in
triplicates. Protein expression was checked by Western blot
analysis.
RNA Extraction and RT-PCR
Total RNA was isolated with TRIZOL Reagent (Invitrogen,
Carlsbad, CA), as suggested by manufacturer’s protocol. One
microgram of mRNA was retro-transcribed using SuperscriptIII with
random examers, according to manufacturer’s protocol. (Invitrogen,
Carlsbad, CA). The following primers were used: AGCTACTG-
TAATGATCAGTCAACG (forward) and AGAGGTCCTTTT-
CACCAGCA (reverse) for 198 bp HPRT fragment amplification;
GACCCGCCAACAAATTAAGA (forward) and TCGTGGTAAA-
CTGGACACCA (reverse) for 215 bp STAT3 fragment amplification.
After a denaturation at 94uC for 3min, 27 and 25 PCR cycles (for
HPRT and STAT3 fragments respectively) were performed (94uCf o r
30 s, 55uC for 30 s, 72uC for 30 s), followed by a final extension at
72uC for 5 min. PCR reactions were performed in a total volume of
20 ml containing 15ng of single strand cDNAs, 1xPCR buffer, 1 mM
MgCl2, 200 mMe a c hd N T P ,0 . 5mM each primer and 0.25U of
AmpliTaq-Gold polymerase (Applied Biosystem, Foster City, CA,
USA). PCR products were separated on 2% agarose gel; images were
acquired by Biorad GelDoc and densitometric analysis of the bands
was performed by Image Quant software.
Immunofluorescence Assay
NF797 cells were plated on glass coverslips, treated or not with
200 nM K252a for 16 hours. Cells were fixed with 3%
paraformaldehyde 2% sucrose, and stained with anti-a-tubulin
monoclonal antibodies, followed by AlexaFluor546 secondary
antibodies (1:500; Molecular Probes, Eugene, OR). Coverslides
were mounted with Prolong Antifade reagent with DAPI
(Molecular Probes, Eugene, OR). Stained cells were observed
with microscope Nikon Eclipse E1000; images were captured with
Nikon DXM digital camera.
Cell Viability Assay
To determine cell growth rate the alamarBlueHAssay (Bio-
source, Nivelles, Belgium) was used, following the supplier
information. Four hundreds cells per well were plated in 96
wells-dishes. After adhesion cells were treated with 100 mM S3I-
201 or 0.3% DMSO as control and the alamarBlue reagent was
added to the medium at 20% v/v. Fluorescence at l= 590nm and
l= 535nm were detected 6, 24 and 48 hours after treatment
using a microplate reader (Tecan). Data were normalized for
values detected 6 hours after addition of alamarBlue reagent.
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